| __timestamp | MorphoSys AG | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9689000 | 1860000 |
| Thursday, January 1, 2015 | 10431000 | 2963000 |
| Friday, January 1, 2016 | 9618000 | 6961000 |
| Sunday, January 1, 2017 | 12348000 | 11779000 |
| Monday, January 1, 2018 | 28310241 | 13697000 |
| Tuesday, January 1, 2019 | 59336147 | 15749000 |
| Wednesday, January 1, 2020 | 159145941 | 18638000 |
| Friday, January 1, 2021 | 199800000 | 27196000 |
| Saturday, January 1, 2022 | 90225000 | 31739000 |
| Sunday, January 1, 2023 | 92538000 | 33491000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of MorphoSys AG and Protagonist Therapeutics, Inc. from 2014 to 2023. Over this period, MorphoSys AG's SG&A expenses surged by approximately 855%, peaking in 2021. This reflects their aggressive expansion and strategic investments. In contrast, Protagonist Therapeutics, Inc. exhibited a more moderate increase of around 1,700%, indicating a steady growth trajectory. Notably, 2020 marked a significant leap for MorphoSys AG, with expenses nearly doubling from the previous year, while Protagonist Therapeutics, Inc. saw a consistent rise, culminating in a 79% increase by 2023. These trends underscore the differing strategic approaches of these companies in navigating the competitive biotech sector.
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MorphoSys AG
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
MorphoSys AG and Evotec SE: SG&A Spending Patterns Compared